Modified single variable domain antibody with reduced combination with drug antibody

• Main Authors: ASHMAN CLAIRE, MORLEY PETER, SANDAL THOMAS, BIRCHLER MARY, DE WILDT RUDOLF M T, LEWIS ALAN PETER, HOLLAND CLAIRE, STEWARD MICHAEL
• Format: Patent
• Language: Chinese; English
• Published: 19.06.2018
• Subjects: CHEMISTRY; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES

The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains, e.g., the human immunoglobulin (antibody) single variable domain, the single variable domain derived from a non-human source, for example the yamma or the camel,e.g., VHH comprising nanobody-(in particular described in e.g., WO 94/04678 and WO 95/04079). The disclosure further relates to uses, formulations and compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of the molecules. 本发明涉及经修饰的蛋白质和肽，其具有降低的与预存抗体结合的能力。此类经修饰的蛋白质/肽分子可以包含C末端添加、延伸或标签和/或某些氨基酸取代。此类经修饰的分子（例如融合物和缀合物）包含蛋白质、肽、抗原结合分子、抗